Mechanism prediction and verification of Xihuang pill against diffuse large B-cell lymphoma
- VernacularTitle:西黄丸抗弥漫大B细胞淋巴瘤的作用机制预测与验证
- Author:
Ruyi HUANG
1
;
Jinyu LI
2
;
Wenqi LIN
3
;
Xin JIANG
2
;
Yanling CHEN
1
;
Weikun HUANG
1
;
Lin YANG
1
Author Information
1. Dept. of Pharmacy，Fujian Cancer Hospital/Clinical Oncology School of Fujian Medical University，Fuzhou 350011，China
2. College of Chemistry，Fuzhou University，Fuzhou 350108，China
3. School of Pharmacy，Fujian University of Traditional Chinese Medicine，Fuzhou 350122，China
- Publication Type:Journal Article
- Keywords:
Xihuang pill;
diffuse large B-cell lymphoma;
network pharmacology;
molecular docking;
molecular dynamics
- From:
China Pharmacy
2026;37(2):161-167
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the mechanism of Xihuang pill （XHP） against diffuse large B-cell lymphoma （DLBCL）. METHODS The active ingredients of XHP and potential therapeutic targets for DLBCL were identified using TCMSP， GeneCards and DisGeNET databases. Protein-protein interaction networks were constructed using the String database and Cytoscape software to screen core components and core targets. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were then performed. The clinical relevance of core targets was analyzed using the GEPIA and PanCanSurvPlot databases. Molecular docking and molecular dynamics （MD） simulation were conducted to verify the interactions between core components and core targets， and the binding free energy was calculated using the molecular mechanics Poisson-Boltzmann surface area （MM-PBSA） method. The effects of XHP on DLBCL and the related molecular mechanisms were validated using CCK-8 assay， flow cytometry and Western blot. RESULTS Network pharmacology analysis identified 108 active ingredients of XHP and 410 potential therapeutic targets for DLBCL. Six core components （e.g.， 17 beta-estradiol， quercetin） and ten core targets [e.g.， tumor protein 53 （TP53）， proto-oncogene tyrosine-protein kinase Src （SRC）] were obtained. Enrichment analysis indicated that the anti-DLBCL effects of XHP were primarily associated with the apoptotic signaling pathway， the phosphoinositide 3-kinase （PI3K）/protein kinase B （Akt） signaling pathway and so on. Clinical correlation analysis revealed that TP53 and SRC expression were significantly up-regulated in DLBCL tissues and associated with poor patient prognosis （P＜0.05）. Molecular docking， MD simulations and MM-PBSA calculations confirmed that the SRC-quercetin complex had a mail：stronger and more stable binding affinity. In vitro experiments demonstrated that XHP concentration-dependently inhibited the proliferation of DLBCL cells； compared with control group， XHP medium- and high-dose groups could significantly induce the apoptosis of SU-DHL2 and SU-DHL4 cells， and significantly down- regulated the expressions of SRC protein， phosphorylated （p）-PI3K/PI3K and p-Akt/Akt in SU-DHL4 cells （P＜0.05）. CONCLUSIONS XHP may inhibit the proliferation and induce the apoptosis of DLBCL cells by regulating the SRC/PI3K/Akt signaling pathway.
